+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Known and potential risks related to the use of high dose intravenous immunoglobulins



Known and potential risks related to the use of high dose intravenous immunoglobulins



Annales de Dermatologie et de Venereologie 124(5): 381-383




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046508795

Download citation: RISBibTeXText

PMID: 9739894


Related references

High-dose intravenous immunoglobulins in HIV-1-infected adults with AIDS-related complex and Walter-Reed 5. Vox Sanguinis 59(Suppl. 1): 3, 1990

Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 56(2): 335-337, 1993

High-dose intravenous immunoglobulins. Journal of Perinatal Medicine 24(5): 539, 1996

The use of high dose intravenous immunoglobulins in dermatology. Journal der Deutschen Dermatologischen Gesellschaft 1(3): 183-190, 2003

Use of high dose intravenous immunoglobulins in dermatology. Journal der Deutschen Dermatologischen Gesellschaft 8(5): 386-7; Author Reply 387-9, 2010

Side effects of high-dose intravenous immunoglobulins. Clinical Neuropharmacology 20(5): 385-393, 1997

Use of high-dose intravenous immunoglobulins in pediatric hematology. La Pediatria Medica e Chirurgica 16(1): 37-41, 1994

High-dose intravenous immunoglobulins in neurocritical care. Intensivmedizin und Notfallmedizin 32(8): 642-650, 1995

Infection prevention strategies in a stem cell transplant unit: impact of change of care in isolation practice and routine use of high dose intravenous immunoglobulins on infectious complications and transplant related mortality. European Journal of Haematology 83(2): 130-138, 2009

High dose intravenous immunoglobulins in guillain barre syndrome. Revue Neurologique (Paris) 145(10): 731-732, 1989

Immunomodulation in myasthenia gravis by high dose intravenous 7 s immunoglobulins. Drachman, D B (Ed ) Annals Of The New York Academy Of Sciences, Vol 505 Myasthenia Gravis: Biology And Treatment; Seventh International Conference, New York, New York, Usa, March 4-7, 1986 Xvii+914p The New York Academy Of Sciences: New York, New York, Usa Illus 828-831, 1987

Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins. Springer Seminars in Immunopathology 23(4): 447-457, 2001

Aseptic meningitis during treatment with high-dose intravenous immunoglobulins. Presse Medicale 25(13): 643, 1996

Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis. Clinical & Experimental Dermatology. 20(2): 164-167, 1995

Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Archives of Neurology 56(6): 661-663, 1999